Skip to search formSkip to main contentSkip to account menu

Adenosine A2A Receptor Antagonist PBF-509

Known as: A2AR Antagonist PBF-509, PBF-509 
An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets
Leukemia develops as the result of intrinsic features of the transformed cell, such as gene mutations and derived oncogenic… 
2018
2018
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
9089Background: ATP is catabolized to adenosine in the tumor microenvironment, leading to excess adenosine and immunosuppressive… 
2018
2018
P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
Highly Cited
2017
Highly Cited
2017
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
Review
2014
Review
2014
Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
  • A. Pinna
  • CNS Drugs
  • 2014
  • Corpus ID: 30098173
Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine, glutamate, adenosine and acetylcholine, are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License